INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41h ago
House PTR1h ago
SEC 13F1h ago
Robinhood Chain1h ago

Most active filers · 30d

  1. 01Kurtz George0B / 239S · 10 late239 trades$59.22M
  2. 02SPSaba Capital Management, L.P.68B / 23S · 14 late91 trades$30.01M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07CFCheng Chi Fung0B / 42S42 trades$15.33M
  8. 08RJRubinstein Julie0B / 37S37 trades$6.25M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  5. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  6. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  7. SELLADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
  8. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K

Form 4 transactions

21,973 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
26
LS
Levy Adam ScottCFO and Secretary
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$346K
10.8K sh
Jan 12, 2026
Page 437 of 550
← PrevNext →
Jan 13, 2026
traded Jan 12, 2026
+1d
SEC Form 4

Evidence

24
HA
Houston AndrewDirector, Chief Executive Officer, 10% Owner
DBXDROPBOX, INC.
Open-market sale · 10b5-1 plan
SELL$655K
23.8K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

23
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$1.12M
16.2K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

23
SE
Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
IRMDIRADIMED CORP
Open-market sale
SELL$476K
4,888 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

23
LJ
Labe JamesDirector, Chief Executive Officer
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$105K
16.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

23
LJ
Labe JamesDirector, Chief Executive Officer
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$159K
23.8K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

23
SS
Srivastava SajalDirector, President and CIO
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$159K
23.8K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

23
SS
Srivastava SajalDirector, President and CIO
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$105K
16.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

23
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$52K
200 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

22
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$426K
1,636 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

22
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$314K
1,200 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

21
CV
Caldwell Nick V.Chief Product Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$530K
75.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
100 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$816K
20.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
VR
Vashisht RijuSenior Vice President
GGenpact LTD
Open-market sale · 10b5-1 plan
SELL$747K
16.0K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

20
DS
Dewan SameerSenior Vice President
GGenpact LTD
Open-market sale · 10b5-1 plan
SELL$704K
15.1K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

20
NK
Nakamura KatsufumiSVP, Chief Customer Officer
ADIANALOG DEVICES INC
Open-market sale
SELL$151K
500 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$686K
9,799 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
GJ
Grayson Blake JeffreyChief Financial Officer
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$455K
6,500 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$194K
738 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

19
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.34M
48.1K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.03M
1,996 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
HR
Howard Justyn RussellDirector, Executive Chair, 10% Owner
SPTSprout Social, Inc.
Open-market sale · 10b5-1 plan
SELL$428K
40.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
AK
Ahn KennethPresident, Hagerty Marketplace
HGTYHagerty, Inc.
Open-market sale · 10b5-1 plan
SELL$643K
50.0K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.28M
2,432 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.27M
2,450 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.06M
2,044 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

18
GK
Gant Kelli K.See remarks
HCCWARRIOR MET COAL, INC.
Open-market sale · 10b5-1 plan
SELL$1.00M
10.0K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$72K
2,170 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

18
BS
Baig SaqibChief Accounting Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$69K
10.0K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$205K
6,348 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

17
AK
Ahn KennethPresident, Hagerty Marketplace
HGTYHagerty, Inc.
Open-market sale · 10b5-1 plan
SELL$18K
1,350 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

17
SE
Susi Roger E.Director, CEO, PRESIDENT, CHAIRMAN, 10% Owner
IRMDIRADIMED CORP
Open-market sale
SELL$11K
112 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$628K
1,199 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$561K
1,094 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$598K
1,135 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$507K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$438K
840 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$758K
1,480 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$692K
1,345 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence